PHARMACEUTICALS
T he pharmaceutical industry is in the midst of another wave of digital transformation. Since the advent of the digital age, a series of distinct digital transformation waves have swept through the sector, with each building on the last to reshape how medicines are discovered, developed and delivered.
The first wave, spanning the 1990s and early 2000s, focused on digitisation at a time when almost every industry was undergoing a similar transition.
Paper-based processes gave way to electronic clinical trial systems and digital laboratory records, improving efficiency but often leaving data locked in siloed systems. The next wave centred on connectivity. The rise of cloud computing, advanced analytics and IoT technologies allowed pharmaceutical companies to link research, manufacturing, supply chains and commercial operations, laying the foundations for a connected, data-driven enterprise.
The arrival of AI marked the third wave. Initially applied to standalone use cases such as drug discovery, clinical trial optimisation and pharmacovigilance, AI quickly proved its value in accelerating research and improving decision-making across the pharmaceutical value chain.
All this digital upheaval has led to today, where the industry finds itself amid its fourth wave of digital transformation, with AI no longer confined to isolated projects or uses.
Instead, pharmaceutical companies are embedding generative AI, foundation models, digital twins and autonomous laboratories throughout core operations, creating AI-native organisations in which intelligent systems underpin every stage of the medicine lifecycle.
THE FOUR WAVES OF PHARMACEUTICAL DIGITAL TRANSFORMATION:
1Digitisation
2Connected
Pharma
3AI and
Automation
4AI-Native
Pharmaceutical Enterprise
78 September 2026